Emergent BioSolutions Announces Interim Results From Phase 2 Study Evaluating CHIKV-VLP, Chikungunya Virus Vaccine Candidate

    NEXT STORY
    Clinical Laboratory Services Market Size Worth USD 274,400 Million by 2023, Predicts Market Research Future
    PREV STORY
    ContraFect Presents Additional Positive Data from the Phase 2 Trial of Exebacase at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01

    author_avatar
    NASDAQ Market News

    Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia

    author_avatar
    NASDAQ Market News

    Phoenix Children’s Is the First-Ever Health System in the U.S to Use Medtronic Stealth Autoguide™ Cranial Robotic Guidance Platform for Neurosurgery

    author_avatar
    NASDAQ Market News